| Literature DB >> 27698753 |
Chejiang Wang1, Jiazhe Wang2, Jianke Feng1.
Abstract
The clinical effects of local application of low-dose insulin in improving wound healing after deep burn self-skin transplantation surgery were examined. Fifty-eight patients with deep burns were selected and randomly divided into 3 groups. In the blank control group, normal saline was injected to the subcutaneous tissue of wounds; in large dose insulin group, 1.0 µ long-term suspended zinc insulin was locally injected; and in the low-dose insulin group, 0.1 µ long-term suspended zinc insulin was locally injected. The healing effects were compared. After 7 and 14 days of treatments, wound surface area in the low-dose group was significantly smaller than in the other groups, and differences were statistically significant (P<0.05); wound healing duration and infection rate for patients in the low-dose group were significantly lower, class A healing rate was significantly improved, and the differences were statistically significant (P<0.05). Insulin resistance index (HOMA-IR) in the low-dose group was significantly lower, insulin secretion index (HOMA-β) and the insulin sensitivity index (HOMA-ISI) significantly increased. The expression levels of vascular endothelial growth factor and tumor necrosis factor-α in local tissue for the low-dose group were significantly higher than those in the other two groups. Differences were statistically significant (P<0.05). In conclusion, local application of low-dose insulin can effectively improve wound healing after deep burn surgeries.Entities:
Keywords: HOMA-IR; HOMA-ISI; HOMA-β; deep burning; insulin; vascular endothelial growth factor; wound healing
Year: 2016 PMID: 27698753 PMCID: PMC5038191 DOI: 10.3892/etm.2016.3645
Source DB: PubMed Journal: Exp Ther Med ISSN: 1792-0981 Impact factor: 2.447
Comparison of wound-healing conditions.
| Wound surface area (% TBSA) | |||||
|---|---|---|---|---|---|
| Groups | 7 days | 14 days | Healing duration (days) | Wound infection [cases (%)] | Class A healing [cases (%)] |
| Control (n=16) | 52.3±9.7 | 42.1±7.8 | 24.1±7.5 | 5 (31.3) | 7 (43.8) |
| Large dose (n=19) | 53.7±9.3 | 43.4±8.1 | 25.3±7.7 | 3 (15.8) | 11 (57.9) |
| Low dose (n=23) | 42.7±8.5 | 33.2±8.1 | 16.4±6.3 | 1 (4.3) | 19 (82.6) |
| F (χ2) | 3.335 | 3.712 | 3.927 | 7.171 | 8.715 |
| P-value | 0.037 | 0.029 | 0.025 | <0.001 | <0.001 |
TBSA, total body surface area.
Comparison of insulin resistance indexes.
| Groups | 7 days HOMA-IR | 14 days HOMA-IR | 7 days HOMA-β | 14 days HOMA-β | 7 days ISI | 14 days ISI |
|---|---|---|---|---|---|---|
| Control | 5.39±0.47 | 4.84±0.52 | 104.35±43.56 | 115.63±46.35 | 1.62±0.17 | 1.74±0.22 |
| Large dose | 5.84±0.42 | 4.85±0.56 | 173.51±50.39 | 191.26±48.52 | 1.75±0.19 | 1.92±0.32 |
| Low dose | 2.34±0.06 | 2.08±0.07 | 295.75±73.62 | 345.62±82.41 | 2.62±0.35 | 2.92±0.46 |
| F | 4.127 | 4.236 | 4.625 | 4.458 | 4.957 | 4.867 |
| P-value | 0.023 | 0.021 | 0.017 | 0.014 | 0.013 | 0.015 |
ISI, insulin sensitivity index.
Comparison of VEGF and TNF-α levels.
| Groups | 7 days VEGF (pg/ml) | 14 days VEGF | 7 days TNF-α (ng/l) | 14 days TNF-α |
|---|---|---|---|---|
| Control | 76.85±24.53 | 75.62±25.74 | 46.92±25.74 | 43.92±21.32 |
| Large dose | 154.67±59.82 | 163.82±44.57 | 65.43±24.57 | 69.87±23.35 |
| Low dose | 264.52±62.34 | 298.61±58.56 | 124.57±43.62 | 165.94±38.37 |
| F | 5.327 | 5.129 | 5.947 | 5.658 |
| P-value | <0.001 | <0.001 | <0.001 | <0.001 |
VEGF, vascular endothelial growth factor; TNF-α, tumor necrosis factor-α.